ELTPELITE PHARMACEUTICALS INC /NV/vs its industry peers
A metric-by-metric comparison of ELITE PHARMACEUTICALS INC /NV/ against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELTPThis | — | — | — | — | 77.1%#1 | 1140.0%#2 | 33.0%#1 | 45.4%#2 | 41.3%#1 | 6#1 | — | — |
| CTTH | — | — | — | — | — | -3454.3%#9 | — | -91.1%#7 | — | — | — | — |
| CVSI | — | — | — | — | -12.2%#3 | 60.0%#4 | -3.4%#2 | -64.0%#5 | -49.0%#4 | 5#2 | — | — |
| CYDY | — | — | — | — | -100.0%#4 | 107.5%#3 | — | — | — | — | — | — |
| CYTOF | — | — | — | — | — | -96.4%#8 | — | -207.6%#8 | — | — | — | — |
| DERM | — | — | — | — | 11.1%#2 | 22.1%#5 | -13.3%#3 | -37.1%#3 | -30.9%#3 | — | -12.7%#2 | — |
| DRUG | — | — | — | — | — | — | — | — | — | — | 125.9%#1 | — |
| EDSA | — | — | — | — | -100.0%#4 | -16.5%#6 | — | -70.5%#6 | — | — | — | — |
| ENLV | — | — | — | — | — | 8329.2%#1 | — | 63.9%#1 | -0.6%#2 | — | — | — |
| EPRX | — | — | — | — | — | -51.3%#7 | — | -47.0%#4 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-08-08.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice